<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Xvivo Perfusion Ab — News on 6ix</title>
<link>https://6ix.com/company/xvivo-perfusion-ab-1</link>
<description>Latest news and press releases for Xvivo Perfusion Ab on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 19:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/xvivo-perfusion-ab-1" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d574c2beedb30cb6f86c2b.webp</url>
<title>Xvivo Perfusion Ab</title>
<link>https://6ix.com/company/xvivo-perfusion-ab-1</link>
</image>
<item>
<title>Late-Breaking Data from PRESERVE Trial Evaluates XVIVO’s HOPE Preservation Approach in Heart Transplantation</title>
<link>https://6ix.com/company/xvivo-perfusion-ab-1/news/late-breaking-data-from-preserve-trial-evaluates-xvivos-hope-preservation-approach-in-heart-transplantation-1</link>
<guid isPermaLink="true">https://6ix.com/company/xvivo-perfusion-ab-1/news/late-breaking-data-from-preserve-trial-evaluates-xvivos-hope-preservation-approach-in-heart-transplantation-1</guid>
<pubDate>Wed, 22 Apr 2026 19:00:00 GMT</pubDate>
<description>TORONTO, April 22, 2026--XVIVO, a global medtech company in the organ transplant industry, today announced late-breaking preliminary data from the PRESERVE Trial (NCT05881278) evaluating hypothermic oxygenated perfusion (HOPE) using the XVIVO Heart Assist Transport™. The trial met its pre-specified primary endpoints and was designed to assess the safety and efficacy for HOPE in the preservation and transport of extended-criteria donor (ECD) hearts with the potential to extend heart preservation</description>
</item>
<item>
<title>The 12-Month Follow-up Results from XVIVO's European Multicenter Heart Trial is Now Published in the European Heart Journal</title>
<link>https://6ix.com/company/xvivo-perfusion-ab-1/news/the-12-month-follow-up-results-from-xvivos-european-multicenter-heart-trial-is-now-published-in-the-european-heart-journal-1</link>
<guid isPermaLink="true">https://6ix.com/company/xvivo-perfusion-ab-1/news/the-12-month-follow-up-results-from-xvivos-european-multicenter-heart-trial-is-now-published-in-the-european-heart-journal-1</guid>
<pubDate>Thu, 16 Apr 2026 12:15:00 GMT</pubDate>
<description>GOTHENBURG, SE / ACCESS Newswire / April 16, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - At last year's ISHLT congress, in April 2025, the one-year results from the European multicenter heart trial, NIHP2019, were presented. The results ...</description>
</item>
<item>
<title>Notice To Attend the Annual General Meeting in XVIVO Perfusion Ab (Publ)</title>
<link>https://6ix.com/company/xvivo-perfusion-ab-1/news/notice-to-attend-the-annual-general-meeting-in-xvivo-perfusion-ab-publ-1</link>
<guid isPermaLink="true">https://6ix.com/company/xvivo-perfusion-ab-1/news/notice-to-attend-the-annual-general-meeting-in-xvivo-perfusion-ab-publ-1</guid>
<pubDate>Thu, 19 Mar 2026 11:50:00 GMT</pubDate>
<description>GOTHENBURG, SE / ACCESS Newswire / March 19, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - (the "Company"), reg. no. 556561-0424, with its registered office in Mölndal, gives notice of the Annual General Meeting to be held on Monday 27 ...</description>
</item>
<item>
<title>CORRECTION FROM SOURCE: The Nomination Committee's Proposal for New Board Members</title>
<link>https://6ix.com/company/xvivo-perfusion-ab-1/news/correction-from-source-the-nomination-committees-proposal-for-new-board-members-1</link>
<guid isPermaLink="true">https://6ix.com/company/xvivo-perfusion-ab-1/news/correction-from-source-the-nomination-committees-proposal-for-new-board-members-1</guid>
<pubDate>Fri, 20 Feb 2026 13:48:00 GMT</pubDate>
<description>This corrects and replaces a release that posted earlier today. GOTHENBURG, SE / ACCESS Newswire / February 20, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Correction: In the press release that was distributed today at 2:00 p.m. CET, ...</description>
</item>
<item>
<title>The Nomination Committee of XVIVO Perfusion AB (publ) Proposes Emil Billbäck and Anne-Karen Hunt as New Members of the Board of Directors</title>
<link>https://6ix.com/company/xvivo-perfusion-ab-1/news/the-nomination-committee-of-xvivo-perfusion-ab-publ-proposes-emil-billback-and-anne-karen-hunt-as-new-members-of-the-board-of-directors-1</link>
<guid isPermaLink="true">https://6ix.com/company/xvivo-perfusion-ab-1/news/the-nomination-committee-of-xvivo-perfusion-ab-publ-proposes-emil-billback-and-anne-karen-hunt-as-new-members-of-the-board-of-directors-1</guid>
<pubDate>Fri, 20 Feb 2026 13:15:00 GMT</pubDate>
<description>GOTHENBURG, SWEDEN / ACCESS Newswire / February 20, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Ahead of the Annual General Meeting to be held on 27 April 2026, the Nomination Committee proposes the re-election of Gösta Johannesson, Camilla ...</description>
</item>
<item>
<title>Management Change at XVIVO - CFO Transitions to New Role</title>
<link>https://6ix.com/company/xvivo-perfusion-ab-1/news/management-change-at-xvivo-cfo-transitions-to-new-role-1</link>
<guid isPermaLink="true">https://6ix.com/company/xvivo-perfusion-ab-1/news/management-change-at-xvivo-cfo-transitions-to-new-role-1</guid>
<pubDate>Thu, 19 Feb 2026 16:00:00 GMT</pubDate>
<description>GOTHENBURG, SWEDEN / ACCESS Newswire / February 19, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - XVIVO Perfusion AB (publ) today announces that the company's CFO, Kristoffer Nordström, has been appointed Senior Vice President Corporate ...</description>
</item>
<item>
<title>Change of Date for Publication of the Interim Report January-March 2026</title>
<link>https://6ix.com/company/xvivo-perfusion-ab-1/news/change-of-date-for-publication-of-the-interim-report-january-march-2026</link>
<guid isPermaLink="true">https://6ix.com/company/xvivo-perfusion-ab-1/news/change-of-date-for-publication-of-the-interim-report-january-march-2026</guid>
<pubDate>Tue, 10 Feb 2026 14:15:00 GMT</pubDate>
<description>GOTHENBURG, SWEDEN / ACCESS Newswire / February 10, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) XVIVO Perfusion AB (publ) has decided to postpone the publication of its interim report for the period January-March 2026. The interim report ...</description>
</item>
<item>
<title>XVIVO's CEO to present at J.P. Morgan's 44th Annual Healthcare Conference in San Francisco</title>
<link>https://6ix.com/company/xvivo-perfusion-ab-1/news/xvivos-ceo-to-present-at-jp-morgans-44th-annual-healthcare-conference-in-san-francisco</link>
<guid isPermaLink="true">https://6ix.com/company/xvivo-perfusion-ab-1/news/xvivos-ceo-to-present-at-jp-morgans-44th-annual-healthcare-conference-in-san-francisco</guid>
<pubDate>Tue, 06 Jan 2026 14:00:00 GMT</pubDate>
<description>GOTHENBURG, SE / ACCESS Newswire / January 6, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, XVIVO announced its participation in the 44th annual J.P. Morgan Healthcare Conference in San Francisco, US, on Wednesday, January 14, ...</description>
</item>
<item>
<title>Interim Report January-September 2025</title>
<link>https://6ix.com/company/xvivo-perfusion-ab-1/news/interim-report-january-september-2025-8</link>
<guid isPermaLink="true">https://6ix.com/company/xvivo-perfusion-ab-1/news/interim-report-january-september-2025-8</guid>
<pubDate>Thu, 23 Oct 2025 05:50:00 GMT</pubDate>
<description>GOTHENBURG, SE / ACCESS Newswire / October 23, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Third quarter 2025 (Jul-Sep) Net sales amounted to SEK 189.1 million (198.5), corresponding to growth of -5 percent in SEK and 1 percent in local ...</description>
</item>
<item>
<title>Nomination Committee of XVIVO Perfusion AB (publ)</title>
<link>https://6ix.com/company/xvivo-perfusion-ab-1/news/nomination-committee-of-xvivo-perfusion-ab-publ</link>
<guid isPermaLink="true">https://6ix.com/company/xvivo-perfusion-ab-1/news/nomination-committee-of-xvivo-perfusion-ab-publ</guid>
<pubDate>Fri, 05 Sep 2025 12:45:00 GMT</pubDate>
<description>GOTHENBURG, SWEDEN / ACCESS Newswire / September 5, 2025 / The following members have been appointed to XVIVO Perfusion's (STO:XVIVO)(LSE:0RKL)(FRA:3XV) nomination committee for the 2026 annual general meeting: Henrik Blomquist, appointed by Bure ...</description>
</item>
<item>
<title>Delay in CE Approval for XVIVO's Perfusion Solution for Heart Preservation</title>
<link>https://6ix.com/company/xvivo-perfusion-ab-1/news/delay-in-ce-approval-for-xvivos-perfusion-solution-for-heart-preservation</link>
<guid isPermaLink="true">https://6ix.com/company/xvivo-perfusion-ab-1/news/delay-in-ce-approval-for-xvivos-perfusion-solution-for-heart-preservation</guid>
<pubDate>Mon, 28 Jul 2025 20:30:00 GMT</pubDate>
<description>GOTHENBURG, SWEDEN / ACCESS Newswire / July 28, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV). The XVIVO Heart Assist Transport and the XVIVO Heart Assist Transport Perfusion Set have received CE approval. At the same time XVIVO estimates ...</description>
</item>
<item>
<title>First Patient Enrolled in US PRESERVE CAP Study for XVIVO Heart Assist Transport Device</title>
<link>https://6ix.com/company/xvivo-perfusion-ab-1/news/first-patient-enrolled-in-us-preserve-cap-study-for-xvivo-heart-assist-transport-device</link>
<guid isPermaLink="true">https://6ix.com/company/xvivo-perfusion-ab-1/news/first-patient-enrolled-in-us-preserve-cap-study-for-xvivo-heart-assist-transport-device</guid>
<pubDate>Mon, 21 Jul 2025 07:20:00 GMT</pubDate>
<description>GOTHENBURG, SE / ACCESS Newswire / July 21, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, XVIVO announces that the first patient has been enrolled as part of the Continued Access Protocol (CAP) study for its heart technology, XVIVO ...</description>
</item>
<item>
<title>Interim Report January-June 2025</title>
<link>https://6ix.com/company/xvivo-perfusion-ab-1/news/interim-report-january-june-2025-7</link>
<guid isPermaLink="true">https://6ix.com/company/xvivo-perfusion-ab-1/news/interim-report-january-june-2025-7</guid>
<pubDate>Fri, 11 Jul 2025 05:50:00 GMT</pubDate>
<description>GOTHENBURG, SE / ACCESS Newswire / July 11, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) A quarter showing a mixed picture Second quarter 2025 (Apr-Jun) • Net sales amounted to SEK 178.3 million (210.3), corresponding to negative growth ...</description>
</item>
<item>
<title>XVIVO Honored with 2025 SACC-USA Business Award for Life-Saving Innovation and Growth in the U.S. Market</title>
<link>https://6ix.com/company/xvivo-perfusion-ab-1/news/xvivo-honored-with-2025-sacc-usa-business-award-for-life-saving-innovation-and-growth-in-the-us-market</link>
<guid isPermaLink="true">https://6ix.com/company/xvivo-perfusion-ab-1/news/xvivo-honored-with-2025-sacc-usa-business-award-for-life-saving-innovation-and-growth-in-the-us-market</guid>
<pubDate>Fri, 13 Jun 2025 12:05:00 GMT</pubDate>
<description>GOTHENBURG, SWEDEN / ACCESS Newswire / June 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Yesterday, XVIVO received the prestigious Swedish American Chamber of Commerce USA (SACC-USA) Business Award 2025, presented at the Swedish ...</description>
</item>
<item>
<title>XVIVO Presents 12-Month Follow-Up Results from European Multicenter Heart Transplantation Trial at ISHLT in Boston</title>
<link>https://6ix.com/company/xvivo-perfusion-ab-1/news/xvivo-presents-12-month-follow-up-results-from-european-multicenter-heart-transplantation-trial-at-ishlt-in-boston</link>
<guid isPermaLink="true">https://6ix.com/company/xvivo-perfusion-ab-1/news/xvivo-presents-12-month-follow-up-results-from-european-multicenter-heart-transplantation-trial-at-ishlt-in-boston</guid>
<pubDate>Tue, 29 Apr 2025 06:20:00 GMT</pubDate>
<description>GOTHENBURG, SE / ACCESS Newswire / April 29, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - The 12-month follow-up results from XVIVO's European multicenter heart trial, NIHP2019, was presented at the 2025 International Society for Heart ...</description>
</item>
<item>
<title>Bulletin from Annual General Meeting in XVIVO Perfusion AB (publ)</title>
<link>https://6ix.com/company/xvivo-perfusion-ab-1/news/bulletin-from-annual-general-meeting-in-xvivo-perfusion-ab-publ</link>
<guid isPermaLink="true">https://6ix.com/company/xvivo-perfusion-ab-1/news/bulletin-from-annual-general-meeting-in-xvivo-perfusion-ab-publ</guid>
<pubDate>Fri, 25 Apr 2025 12:30:00 GMT</pubDate>
<description>GOTHENBURG, SWEDEN / ACCESS Newswire / April 25, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Perfusion AB (publ) ("XVIVO Perfusion" or the "Company") ...</description>
</item>
<item>
<title>Interim Report January-March 2025</title>
<link>https://6ix.com/company/xvivo-perfusion-ab-1/news/interim-report-january-march-2025-8</link>
<guid isPermaLink="true">https://6ix.com/company/xvivo-perfusion-ab-1/news/interim-report-january-march-2025-8</guid>
<pubDate>Thu, 24 Apr 2025 05:50:00 GMT</pubDate>
<description>GOTHENBURG, SE / ACCESS Newswire / April 24, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) First quarter 2025 (Jan-Mar) Net sales increased to SEK 218.6 million (186.0), corresponding to growth of 18 percent in SEK and 16 percent in local ...</description>
</item>
</channel>
</rss>